Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13964615 | 0.81 | AR (0.46) | ARBRD4MAPTGAAPRCP | |
| SCHEMBL4978935 | 0.81 | PRCP (0.55) | ARBRD4MAPTGAAPRCP | |
| SCHEMBL29779937 | 0.81 | PRCP (0.55) | ARBRD4MAPTGAAPRCP | |
| SCHEMBL2998270 | 0.78 | AR (0.46) | ARBRD4MAPTGAAPRCP | |
| SCHEMBL30101768 | 0.78 | AR (0.46) | ARBRD4MAPTGAAPRCP | |
| SCHEMBL13964738 | 0.77 | KDM4E (0.53) | ARMAPTGAAKDM4EMEN1 | |
| SCHEMBL19155153 | 0.70 | AR (0.42) | ARBRD4MAPTGAAPRCP | |
| SCHEMBL22857208 | 0.70 | AR (0.42) | ARBRD4MAPTGAAPRCP | |
| SCHEMBL22200115 | 0.70 | AR (0.42) | ARBRD4MAPTGAAPRCP | |
| SCHEMBL7900671 | 0.69 | CHRNB2 (0.50) | ARMAPTGAAKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147334-A9 | 13-OXIDIZED INGENOL DERIVATIVE AND USE THEREOF | Tianjin Zhongxin Pharmaceutical Group Corp., Ltd. Research Institute Branch Company (CN) | 2021-05-20 | — | — | US | disclosed |
| US-20200140369-A1 | 13-OXIDIZED INGENOL DERIVATIVE AND USE THEREOF | Tianjin Zhongxin Pharmaceutical Group Corp., Ltd. Research Institute Branch Company (CN) | 2020-05-07 | — | — | US | disclosed |
| EP-3636628-A1 | 13-OXIDIZED INGENOL DERIVATIVE AND USE THEREOF | Tianjin Zhongxin Pharmaceutical Group Corp., Ltd. Research Institute Branch Company (CN) | 2020-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147334-A9 | 13-OXIDIZED INGENOL DERIVATIVE AND USE THEREOF | MMP8, CXCL8, PMAIP1 | AR 2661/4885BRD4 2665/4885MAPT 4800/4885 |
| US-20200140369-A1 | 13-OXIDIZED INGENOL DERIVATIVE AND USE THEREOF | MMP8, CXCL8, PMAIP1 | AR 2661/4885BRD4 2665/4885MAPT 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.